Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
Russell MD, Yang Z, Dooley N, Gibson M, Zuckerman B, Adas MA, Alveyn E, Patel S, Bechman K, Price E, Gallagher S, Coalwood C, Cope AP, Norton S, Galloway JB. Russell MD, et al. Among authors: bechman k. Rheumatology (Oxford). 2024 Nov 1:keae607. doi: 10.1093/rheumatology/keae607. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39485485
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.
Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB. Russell MD, et al. Among authors: bechman k. Lancet Rheumatol. 2024 Oct 15:S2665-9913(24)00221-2. doi: 10.1016/S2665-9913(24)00221-2. Online ahead of print. Lancet Rheumatol. 2024. PMID: 39423845 Free article.
The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.
Mercer L, Abhishek A, Kavirayani A, Ahmed A, Davidson A, Foulkes A, Jones C, Nash C, Rose-Parfitt E, Dhillon E, Zabate G, Twohig H, De Vere H, Scott J, Reynolds J, Holmes J, Hartley K, Warrier K, Nowak K, Parsons K, Bechman K, Bray L, Adikari M, Wood N, Faithfull N, Gullick N, Saha P, Heaton R, Deepak S, Hider S, Khalid S, Said SS, Ryan S, Kyle S, Raghuvanshi S, Tan SY, Shivamurthy V, Galloway J. Mercer L, et al. Among authors: bechman k. Rheumatol Adv Pract. 2024 Jul 12;8(3):rkae077. doi: 10.1093/rap/rkae077. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 39006537 Free PMC article. Review.
OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate.
Brown AD, Fisher L, Curtis HJ, Wiedemann M, Hulme WJ, Speed V, Hopcroft LEM, Cunningham C, Costello RE, Galloway JB, Russell MD, Bechman K, Kurt Z, Croker R, Wood C, Walker AJ, Schaffer AL, Bacon SCJ, Mehrkar A, Hickman G, Bates C, Cockburn J, Parry J, Hester F, Harper S, Goldacre B; OpenSAFELY Collaborative; MacKenna B. Brown AD, et al. Among authors: bechman k. Br J Clin Pharmacol. 2024 Apr 8:10.1111/bcp.16062. doi: 10.1111/bcp.16062. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 38589944 Free PMC article.
The influence of safety warnings on the prescribing of JAK inhibitors.
Russell MD, Yang Z, Walter B, Alveyn E, Bechman K, Miracle A, Nagra D, Adas MA, Norton S, Cope AP, Langan SM, Galloway JB. Russell MD, et al. Among authors: bechman k. Lancet Rheumatol. 2024 Mar;6(3):e138-e139. doi: 10.1016/S2665-9913(24)00002-X. Epub 2024 Feb 1. Lancet Rheumatol. 2024. PMID: 38310922 No abstract available.
61 results